Abstract: A folding pet bed includes a frame with a top face and a bottom face and includes: a spine; a first and second frame plates coupled to the spine to form rotating joints; the first and second frame plates including flexible arms, where each of the flexible arms includes a first end fixably coupled to the corresponding frame plate and a second end not fixably coupled to the corresponding frame plate; and a plurality of casters coupled to the second ends of the flexible arms at the bottom face of the frame. The pet bed further includes trays coupled to the frame plates at the top face of the frame upon which a pet may rest. The trays may be rotated toward each other to place the pet bed in a folded position for easy movement and storage.

Abstract: A folding pet bed includes a frame with a top face and a bottom face and includes: a spine; a first and second frame plates coupled to the spine to form rotating joints; the first and second frame plates including flexible arms, where each of the flexible arms includes a first end fixably coupled to the corresponding frame plate and a second end not fixably coupled to the corresponding frame plate; and a plurality of casters coupled to the second ends of the flexible arms at the bottom face of the frame. The pet bed further includes trays coupled to the frame plates at the top face of the frame upon which a pet may rest. The trays may be rotated toward each other to place the pet bed in a folded position for easy movement and storage.

Abstract: Methods for treating spondyloarthropathies, including ankylosing spondylitis, using TNF? inhibitors are described.

Abstract: The invention describes methods of treating depression comprising administering a TNF? antibody, such as a human TNF? antibody.

Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Abstract: The invention describes methods of treating depression comprising administering a TNF? antibody, such as a human TNF? antibody. The invention also provides a method for treating depression comprising inhibiting TNF? activity in a subject suffering from depression by systemically administering to the subject a human anti-TNF? antibody, or an antigen-binding portion thereof, such that depression is treated. Also described is a method for the treatment or alleviation of depression or other affective disorders comprising administering an amount of an anti-inflammatory agent effective to treat or alleviate depression or other affective disorder to a subject in need thereof, wherein said anti-inflammatory agent down-regulates peripheral cytokine levels to thereby treat or alleviate depression or other affective disorder.

Abstract: The invention describes methods of treating and preventing respiratory syncytial virus (RSV) infection comprising administering a TNF inhibitor and an additional therapeutic agent. The invention also describes methods of treating and preventing respiratory syncytial virus (RSV) infection comprising administering an anti-TNF antibody and an anti-RSV antibody.

Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.